Cargando…

Immunohistochemistry Staining-Proven Cytomegalovirus Colitis in Living Donor Liver Transplantation

Background and Aims: Cytomegalovirus (CMV) infection is a common occurrence in liver transplantation (LT) even in an era of preventive strategies. However, the diagnosis of CMV colitis remains challenging. This study aimed to focus on the clinical significance of endoscopic biopsy-proven CMV colitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Shu-Hsien, Wu, Kun-Ta, Wang, Chih-Chi, Liu, Ting-Ting, Eng, Hock-Liew, Chiu, King-Wah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862431/
https://www.ncbi.nlm.nih.gov/pubmed/36680155
http://dx.doi.org/10.3390/v15010115
_version_ 1784875090878398464
author Lin, Shu-Hsien
Wu, Kun-Ta
Wang, Chih-Chi
Liu, Ting-Ting
Eng, Hock-Liew
Chiu, King-Wah
author_facet Lin, Shu-Hsien
Wu, Kun-Ta
Wang, Chih-Chi
Liu, Ting-Ting
Eng, Hock-Liew
Chiu, King-Wah
author_sort Lin, Shu-Hsien
collection PubMed
description Background and Aims: Cytomegalovirus (CMV) infection is a common occurrence in liver transplantation (LT) even in an era of preventive strategies. However, the diagnosis of CMV colitis remains challenging. This study aimed to focus on the clinical significance of endoscopic biopsy-proven CMV colitis in patients following living donor liver transplantation (LDLT). Methods: From January 2007 to December 2021, a total of 55 CMV colitis cases were retrospectively enrolled and divided into a non-LDLT group in 53 and an LDLT group in 2 cases. Clinical demographics, diagnostic measurement, histopathology, and anti-viral therapy were investigated. Results: There were 1630 cases undergoing LDLT in the period 2007–2021, with only 2 recipients being confirmed to have CMV colitis in 2021 (2/114, 1-year incidence: 1.75%). Comparisons between the 53 non-LDLT cases and 2 LDLT cases are as follows: Serum anti-CMV immunoglobulin M (IgM) was shown to be positive (n = 3, 5.5% vs. n = 0, p = 1.0) and negative (n = 20, 37.7% vs. n = 2, 100%, p = 0.16); anti-CMV immunoglobulin G (IgG) was positive (n = 19, 35.8% vs. n = 2, 100%, p = 0.14) and none were negative; CMV DNAemia was shown to be detectable (n = 14, 26.4% vs. n = 1, 50%, p = 0.47) and undetectable (n = 14, 26.4% vs. n = 1, 50%, p = 0.47). Among the two recipients with CMV colitis, one had CMV DNAemia and the other had no CMV DNAemia upon the development of symptoms; negative anti-CMV-IgM and positive anti-CMV-IgG were observed both pre-transplant and post-transplant; finally, CMV colitis was documented based on the presence of inclusion bodies and positive immunohistochemistry (IHC) staining in histology. Conclusion: Patients with immunocompromised status, in particular organ transplantation, may have positive serum anti-CMV IgM/IgG antibodies both before and after transplantation. This study emphasized the fact that endoscopic biopsy with IHC staining may be a more powerful tool for making an accurate diagnosis of CMV colitis in the setting of living donor liver transplantation.
format Online
Article
Text
id pubmed-9862431
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98624312023-01-22 Immunohistochemistry Staining-Proven Cytomegalovirus Colitis in Living Donor Liver Transplantation Lin, Shu-Hsien Wu, Kun-Ta Wang, Chih-Chi Liu, Ting-Ting Eng, Hock-Liew Chiu, King-Wah Viruses Article Background and Aims: Cytomegalovirus (CMV) infection is a common occurrence in liver transplantation (LT) even in an era of preventive strategies. However, the diagnosis of CMV colitis remains challenging. This study aimed to focus on the clinical significance of endoscopic biopsy-proven CMV colitis in patients following living donor liver transplantation (LDLT). Methods: From January 2007 to December 2021, a total of 55 CMV colitis cases were retrospectively enrolled and divided into a non-LDLT group in 53 and an LDLT group in 2 cases. Clinical demographics, diagnostic measurement, histopathology, and anti-viral therapy were investigated. Results: There were 1630 cases undergoing LDLT in the period 2007–2021, with only 2 recipients being confirmed to have CMV colitis in 2021 (2/114, 1-year incidence: 1.75%). Comparisons between the 53 non-LDLT cases and 2 LDLT cases are as follows: Serum anti-CMV immunoglobulin M (IgM) was shown to be positive (n = 3, 5.5% vs. n = 0, p = 1.0) and negative (n = 20, 37.7% vs. n = 2, 100%, p = 0.16); anti-CMV immunoglobulin G (IgG) was positive (n = 19, 35.8% vs. n = 2, 100%, p = 0.14) and none were negative; CMV DNAemia was shown to be detectable (n = 14, 26.4% vs. n = 1, 50%, p = 0.47) and undetectable (n = 14, 26.4% vs. n = 1, 50%, p = 0.47). Among the two recipients with CMV colitis, one had CMV DNAemia and the other had no CMV DNAemia upon the development of symptoms; negative anti-CMV-IgM and positive anti-CMV-IgG were observed both pre-transplant and post-transplant; finally, CMV colitis was documented based on the presence of inclusion bodies and positive immunohistochemistry (IHC) staining in histology. Conclusion: Patients with immunocompromised status, in particular organ transplantation, may have positive serum anti-CMV IgM/IgG antibodies both before and after transplantation. This study emphasized the fact that endoscopic biopsy with IHC staining may be a more powerful tool for making an accurate diagnosis of CMV colitis in the setting of living donor liver transplantation. MDPI 2022-12-30 /pmc/articles/PMC9862431/ /pubmed/36680155 http://dx.doi.org/10.3390/v15010115 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lin, Shu-Hsien
Wu, Kun-Ta
Wang, Chih-Chi
Liu, Ting-Ting
Eng, Hock-Liew
Chiu, King-Wah
Immunohistochemistry Staining-Proven Cytomegalovirus Colitis in Living Donor Liver Transplantation
title Immunohistochemistry Staining-Proven Cytomegalovirus Colitis in Living Donor Liver Transplantation
title_full Immunohistochemistry Staining-Proven Cytomegalovirus Colitis in Living Donor Liver Transplantation
title_fullStr Immunohistochemistry Staining-Proven Cytomegalovirus Colitis in Living Donor Liver Transplantation
title_full_unstemmed Immunohistochemistry Staining-Proven Cytomegalovirus Colitis in Living Donor Liver Transplantation
title_short Immunohistochemistry Staining-Proven Cytomegalovirus Colitis in Living Donor Liver Transplantation
title_sort immunohistochemistry staining-proven cytomegalovirus colitis in living donor liver transplantation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862431/
https://www.ncbi.nlm.nih.gov/pubmed/36680155
http://dx.doi.org/10.3390/v15010115
work_keys_str_mv AT linshuhsien immunohistochemistrystainingprovencytomegaloviruscolitisinlivingdonorlivertransplantation
AT wukunta immunohistochemistrystainingprovencytomegaloviruscolitisinlivingdonorlivertransplantation
AT wangchihchi immunohistochemistrystainingprovencytomegaloviruscolitisinlivingdonorlivertransplantation
AT liutingting immunohistochemistrystainingprovencytomegaloviruscolitisinlivingdonorlivertransplantation
AT enghockliew immunohistochemistrystainingprovencytomegaloviruscolitisinlivingdonorlivertransplantation
AT chiukingwah immunohistochemistrystainingprovencytomegaloviruscolitisinlivingdonorlivertransplantation